Indian drugmaker Hikma has agreed in principle to a $150 million settlement to resolve lawsuits claiming that it contributed to the opioid crisis in the US, which could allow it to put the litigation in the rear-view mirror.
Under the terms of the agreement, Hikma would pay up to $115 million in cash and $35 million in donations of naloxone, an opioid antagonist used to reverse the effects of opioid overdose, to resolve “the vast majority” of opioid-related cases brought against it.
